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Abstract  
Purpose: to systematically review the current evidence on the effects of aerobic and resistance exercise in late-
onset Pompe disease patients treated with enzymatic replacement therapy. 
Methods: a systematic search of the literature was conducted on Academic Search Complete, Medline with full 
text, SPORTDiscus, Pubmed, and Science Direct electronic databases. In addition, cross-referencing and 
manual search of printed journals was performed. The eligibility criteria were (a) experimental or quasi-
experimental research design; (b) intervention with aerobic exercise, resistance exercise, or both; (c) published 
studies until August 2016; (d) studies published in English, Spanish, French or Portuguese; (e) studies on 
human beings. This systematic review was reported in accordance with the PRISMA statement. 
Results: of the 166 citations identified, 4 met the eligibility criteria and were included in the review. All studies 
had a small sample size, and ranged from 5 to 23 participants. In three of the studies, the training programs 
allowed subjects to improve physical parameters like muscular strength, endurance, core stability, and to 
decrease pain and fatigue. Overall, body composition remained unchanged.  
Conclusions: the results found in this review suggest that aerobic and resistance training may be beneficial in 
this population. There is a need for additional, larger sample sizes, longer studies with more homogeneous 
training programs on this topic. 




Among metabolic myopathies, Pompe disease belongs to glycogen storage diseases, also known as 
glycogenoses (thus, it is also called glycogenosis type II). First described in 1932, it is estimated that this rare, 
autosomal recessive disease affects 1 in 40,000 live births worldwide 
[1]
. It is caused by lysosomal acid alpha-
glucosidase gene defects (GAA, OMIM number 606800), for which more than 300 mutations have been 
described 
[2]
, having as a direct consequence the accumulation and deposition of glycogen in multiple organs, as 
GAA catalyzes the breakdown of glycogen into glucose in lysosomal acid environment 
[3]
.  
In its infantile-onset form, the most severe clinical manifestations of Pompe disease are respiratory 
distress and heart failure, both in association with hypertrophic cardiomyopathy secondary to glycogen’s 
deposition. On the other hand, in late-onset forms patients are mainly affected by progressive muscular 
weakness, with less cardiac and respiratory compromise 
[4]
. The severity and clinical evolution of the disease 
vary depending on the specific mutation 
[5]
, with a range from less than 1% enzyme activity in most serious 
cases and up to 30% in moderate ones 
[1]
. 
Nowadays, Pompe disease is the only glycogenosis for which a specific treatment exists 
[6]
. In 2006, 
the United States, Europe and some other countries approved a biweekly 20 mg/kg enzymatic replacement 
therapy (ERT), administered intravenously with dose adjustment depending on tolerance or the presence of 
adverse events 
[7]
. Since then, several clinical trials and observational studies have been developed to describe 
ERT effects on Pompe disease clinical evolution among children, adolescents and adults 
[7, 8]
. This systematic 
review aims to evaluate the evidence on the benefits of aerobic and resistance exercise in late-onset Pompe 
disease patients treated with ERT, to identify scopes, limitations in current knowledge and possible actions in 
future research on this topic. 
 
II. Methodology 
2.1 Search strategy 
Studies were retrieved between January and August 2016 based on the terms “exercise” and “Pompe 
disease” as well as related terms or synonyms (i.e., “training,” “glycogen storage disease type II”) on the 
following electronic databases: (1) Academic Search Complete, (2) Medline with full text, (3) SPORTDiscus, 
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(4) Pubmed and (5) Science Direct. An example (Pubmed) of the search strategy is (("exercise"[MeSH Terms] 
OR "exercise"[All Fields]) AND ("glycogen storage disease type ii"[MeSH Terms] OR ("glycogen"[All Fields] 
AND "storage"[All Fields] AND "disease"[All Fields] AND "type"[All Fields] AND "ii"[All Fields]) OR 
"glycogen storage disease type ii"[All Fields] OR ("pompe"[All Fields] AND "disease"[All Fields]) OR "pompe 
disease"[All Fields])) AND "humans"[MeSH Terms].  Specific research filters were applied in each database in 
order to better adjust the search according to eligibility criteria.  
Studies that were not available as free full texts were tracked by librarians from the University of Costa 
Rica in order to purchase them or to contact authors for free access. In addition to electronic database research, a 
manual cross-referencing search was conducted alongside retrieved reviews and printed journals to identify 
potentially eligible studies. There were no restrictions on publication dates. The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Statement 
[9]
 was used to conduct and report this systematic 
review. All files were managed and stored in Mendeley Desktop® version 1.15.3. All data extracted from each 
study was coded and organized using Microsoft Excel® 2010. 
 
2.2 Selection criteria 
To be included, studies met the following eligibility criteria: (1) experimental or quasi-experimental 
research design; (2) exercise intervention with aerobic, resistance training, or both; (3) studies published until 
February 2016 August 2016; (4) studies published in English, Spanish, French or Portuguese; (5) studies in 
humans.  
 
2.3 Study selection and data abstraction  
Study selection and data abstraction were performed by the two authors, independently from each 
other. The following information was extracted: authors’ information, publication year, publication country, age 
and sex of participants, disease duration since diagnosis and time since ERT began, sample sizes, characteristics 
of the exercise interventions (duration, frequency, intensity, length of each session, mode of training and 
supervision of exercise), outcomes measured and measuring instruments. Then, a meeting was scheduled to 
compare findings and discrepancies regarding eligibility, and data abstraction was resolved by consensus.  
 
III. Results 
Fig. 1 shows the PRISMA flow diagram of the search process, including the reasons for exclusion. 
Manual search and printed journals results are not shown on the “Identification” box because the results found 
were duplicates and, therefore, removed. Of the 166 citations identified, four met the eligibility criteria and were 
included in this review. Additional file 1 shows a list of each excluded study (n = 115), including the reason for 
the exclusions in each case. TABLE 1 describes exercise interventions and summarizes other important 
characteristics of included studies. 
Each study had a small number of participants, which ranged from 5 to 23. There were 17 women 
(51.52%) and 16 men (48.48%) including all the four studies. Half of interventions were conducted in Greece 
and the other half in Holland. Findings reported by Favejee et al. 
[10]
 were based on the intervention described by 
van den Berg et al. 
[11]
. Both authors evaluated multiple outcomes from the same sample, which explains why 
table 1 shows the same participant and intervention descriptions for both studies.  
The 12 week aerobic, resistance training with core stability intervention conducted by van den Berg et 
al. 
[11]
 proved to be safe according to plasma creatine kinase, pain and fatigue periodic tests, and also allowed the 
participants to significantly increase their endurance (workload capacity before intervention 110 W, and 122 W 
after, 95% confidence interval of 6.0 to 19.7), maximum oxygen uptake (p <0.01) and ventilatory threshold      
(p <0.01); in addition, muscle strength of the hip flexors and shoulder abductors increases significantly (p <0.01 
and p = 0.02, respectively). In respect to muscle function, the participants spent less time climbing four steps    
(p = 0.02) and rising from supine to standing positions (p = 0.05). Furthermore, they increased their times in 
balance for each of the core exercises. On the contrary, Quick Motor Function Test  
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Fig 1. Flow diagram for research strategy and study selection, in accordance with PRISMA statement 
 
TABLE 1. Main characteristics of the studies included 
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RT (resistance training); HR (heart rate); MHR (maximum heart rate); RM (repetition maximum); BPM (beats per 
minute); ERT (enzyme replacement therapy); QMFT (Quick Motor Function Test); FSS (Fatigue Severity Scale); R-PAct 
(Rasch-built Pompe-specific Activity Scale); SF-36 (Medical Outcomes Study 36-Item Short-Form Health Survey); DXA 
(dual X-ray absorptiometry); 6MWT (6-minute walking test). 
(QMFT) scores, time to run 10 meters, and body composition (evaluated through dual X-ray 
absorptiometry) remained unchanged.  
On the other hand, Favejee et al. found that the exercise intervention conducted by van den Berg et al. 
also decreased significantly both fatigue (p = 0.01) and pain (p = 0.04) among participants 
[10, 11]
. Nevertheless, 
those changes were not correlated to the improvement in the physical parameters described by van den Berg et 
al. 
[11]
. In addition, muscle function self-report scores, the amount of physical activity (measured through 
accelerometry) and general health status scores remained unchanged. 
Terzis et al. 
[12]
 discovered that 20 weeks of supervised aerobic and resistance training enhanced 
muscular strength (p <0.05) for hip extensions, bench pressing and rowing, as well as the distance covered in the 
6-minute Walking Test (p <0.01). Regarding body composition, lean body mass in upper limbs increased         
(p <0.05); however, no changes in the body fat or in the bone mineral density were observed. Likewise, in a 
subsequent study conducted by Terzis et al. 
[13]
 in which the effects of physical exercise during the ERT infusion 
was evaluated after 6 months of training, no improvements in body composition, muscular strength or the 
distance covered in the 6-minute Walking Test were found. 
 
IV. Discussion 
The aim of this systematic review was to evaluate the current evidence on the benefits of aerobic 
exercise, resistance training or their combination in late-onset Pompe disease patients treated with ERT. The 
findings suggest that interventions with physical exercise in this population may enhance muscular strength and 
endurance, along with a decrease in pain and fatigue. Furthermore, according to van den Berg et al. 
[11]
 those 
improvements seem to be independent of the beneficial effects of ERT alone, a finding that suggests that 
exercise may be recommended as a complementary, non-pharmacological, effective treatment in the clinical 
management of these patients. Nevertheless, these results must be interpreted with caution, due to small sample 
sizes and the short length of the studies conducted on this topic so far. 
In recent years, some investigations have examined the effectiveness of aerobic and resistance training 
among patients with other muscle diseases. For instance, Voet et al., based on findings from randomized and 
quasi-randomized controlled trials, concluded that there was insufficient evidence to support the prescription of 
resistance training in patients diagnosed with myotonic dystrophy and facioscapulohumeral dystrophy 
[14]
; on 
the contrary, in patients with mitochondrial myopathies the combination of aerobic exercise and resistance 
training appeared to be safe, and allowed participants to improve submaximal aerobic endurance. Similar results 
for several myopathies were found by Féasson et al. in their review 
[15]
.  
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Correspondingly, other muscle glycogenoses have been studied to determine the benefits of physical 
exercise, as in McArdle disease (glycogenosis type V). So far, the findings indicate that aerobic exercise 
improves exercise tolerance and endurance 
[16–18]
. In addition, the review by Lucia et al. includes nutritional 
recommendations as well as exercise prescription examples for these patients 
[19]
. Despite all of the above, until 
now no high methodological quality randomized or quasi-randomized controlled trials have been conducted 
with McArdle patients to evaluate the effects of exercise 
[20]
, just like in Pompe disease for which, to the best of 
the author’s knowledge, no randomized controlled trials have been conducted or published so far.  
Several observational studies have reported favorable changes in muscular strength, muscle function, 
endurance, fatigue and quality of life among patients with late-onset Pompe disease 
[21–27]
. However, such 
studies focused on describing and reporting the effects of ERT on those outcomes (for example, motor function 
or endurance before and after ERT administration), which prevent to conclude on the effects of exercise per se, 
independently from ERT known benefits.  
The findings of this systematic review, as well as the observed heterogeneity in the design of exercise 
interventions, lead us to recommend that future studies on this field include larger samples. In spite of the low 
incidence of glycogenosis type II, and considering that the blinding of participants in exercise interventions is 
probably impossible, we suggest that randomized or quasi-randomized trials are conducted to increase 
methodological quality and conclude with greater certainty about the effectiveness of aerobic and resistance 
training in this specific population. 
 
V. Conclusion 
In summary, despite only four studies met inclusion criteria, our findings suggest that physicians and 
sport coaches may prescribe physical exercise as an adjunct, inexpensive, safe and effective treatment to 
improve aerobic endurance, muscular strength and function in patients with late-onset Pompe disease treated 
with enzymatic replacement therapy. There is a need for additional, larger sample sizes, longer studies with 
more homogeneous training programs on this topic to give more accurate recommendations when prescribing 
exercise in this population. 
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